LunchTime Series Webinar Wednesday, February 26, 2014 at 12:00PM-PST
Topic: “Health Care Reform – Challenges of Implementation”
Presented by: Tracy Baroni Allmon
For more information please email firstname.lastname@example.org
Celgene Corporation cordially invites you to participate in a program titled: POMALYST® (pomalidomide):
Overview of Prescribing Information
Presented by: James Berenson, MD, Institute for Myeloma & Bone Cancer Research in West Hollywood, CA.
Wednesday, February, 26, 2014 at 5:30pm-6:30pm PST. To register for this program, please e-mail email@example.com your name, degree, institution, phone number, and e-mail address. You may also register by calling Amy Tarleton, Envision Communications, at (770)984-5117. If you have any questions about this program, please contact the Celgene representative, Michael Foster, at (562)754-7604 or firstname.lastname@example.org. In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this promotional program is limited to healthcare professionals. Accordingly, attendance by nonclinical guests or spouses is not permitted.
This program is held in conjunction with MOASC. This is a promotional program and no CME credits are offered.
Please click on the banner above to learn more.
MOASC & ANCO members residing in Representative Kevin McCarthy's 23rd District (Central Valley & Bakersfield) are asked to e-mail the Majority Whip of the U.S. House of Representatives, before this Wednesday, February 26th, requesting him to urge his colleagues to enact the SGR Repeal and Medicare Provider Payment Modernization Act of 2014, (HR4015/S2000),before the current Medicare physician payment "bridge" expires in March. ASCO & MOASC have sent their letter to Rep. McCarthy, and now we ask for your support to help apply additional pressure to the congressman. Please email Rep. McCarthy a letter on behalf of you patients. We have already written the attached draft letter, tailored to you, for your convenience. Please feel free to edit the letter however you see necessary. We wanted to provide you with as much support as possible to make this an easy lift for you, as we appreciate your busy schedules. You can simply update the, copy the letter onto your letterhead template, sign it, attach to an email, and send to: Brandon Eden, Health Legislative Assistant, email@example.com We would like the leadership offices to have received the letters by Wednesday, February 26 - The House and Senate will be in session this week (2/24-2/28), so it would be ideal to get the letters into the session by Wednesday. We are doing a targeted push of congressional leadership currently and your voices are crucially important! (If that is not possible because of the quick turnaround time, the letters are still crucially important past that date. The committee's final decision deadline is March 31.)
Learn about this very important legislation at http://www.asco.org/advocacy/sgr-repeal-bill-introduced. Read ASCO's letter at http://www.asco.org/advocacy/asco-urges-congress-enact-sgr-repeal-legislation. ANCO and MOASC urge you to contact your Congressional Representatives on this matter via http://capwiz.com/asco/issues/alert/?alertid=63090166
For more information, please click here.
CMS is extending the deadline for eligible professionals to attest to meaningful use for the Medicare EHR Incentive Program 2013 reporting year from February 28, 2014 to March 31, 2014, 11:59 pm ET/8:59 pm Pacific. This extension will allow more time for providers to submit their meaningful use data and receive an incentive payment for the 2013 program year, as well as avoid the 2015 payment adjustment. This extension does not impact the deadlines for the Medicaid EHR Incentive Program or any other CMS program, including the electronic submission for the Physician Quality Reporting System EHR Incentive Program Pilot. If you are an eligible professional working on your attestation for the 2013 reporting period, there are resources available to help you with the registration and attestation process. Stage 1 Meaningful Use Calculator; Registration and Attestation User Guides; EHR Incentive Program Website. The EHR Information Center is open to assist you with all of your registration and attestation system inquiries. Please call, 1-888-734-6433 (primary number) or 888-734-6563 (TTY number). The EHR Information Center is open Monday through Friday from 7:30 a.m. - 6:30 p.m. (Central Time), except federal holidays. Please click here for more information.
New CMS-1500 Claim Form Must Be Submitted on April 1, 2014
The CMS-1500 claim form has been updated for ICD-10. Form Version 02/12 will replace the CMS-1500 claim form, 08/05, effective for claims received on/after April 1, 2014. Read the complete update. For more information, please click here.
In parts of California, the shortage of doctors participating in California's new insurance exchange is providing new leverage for medical providers to hold out for higher reimbursement rates from big insurance companies, and in some instances, the insurers are often caving in to the doctors, raising concerns that the trend could catch on and drive up the price of health insurance premiums on the exchange. Many doctors are upset about the discounted reimbursement rates that insurers have imposed on them to keep premiums low on the Covered California exchange. The new rates, as much as 30 percent lower than those paid by non-exchange plans, took effect Jan. 1, 2014, when the new health care plans of hundreds of thousands of Californians kicked in. For more information, please click here.
Noridian/JEMAC's latest round of mass adjustments for inappropriately denied ESA claims stemming from an error made in the transition from Palmetto/J1MAC was scheduled to have been completed on February 18. If you have not had past ESA claims denials reversed, or if current ESA claims continue to be denied, please let ANCO and MOASC know, so that we can inform Noridian/JEMAC. In addition, appeal the inappropriately denied claims referencing the December 4th and January 28th Noridian/JEMAC website alerts and notices. For more information, please click here.
The Department of Health Care Services (DHCS) recently added information to its website relating to pharmacy payment reductions as part of Assembly Bill 97 and State Plan Amendment (SPA) 12-014. The information is available on the Pharmacy Benefits Division and Vision Care Program page of the DHCS website. Providers are encouraged to bookmark this page and visit it often for the most up-to-date information on AB 97 pharmacy payment reductions and SPA 12-014. For more information, please click here.
MOASC would like to introduce two of our newest sponsor’s:
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient’s lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient’s lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad offers an array of genetic tests, prognostic tests and personalized medicine tests to help healthcare providers assess a patient's increased cancer risk, disease aggressiveness and optimize efficacy of chemotherapy. Myriad's testing products can provide healthcare providers with information to help make medical management decisions to reduce cancer risk and help make sure specific treatments are tailored for each individual patient. For more information, visit https://www.myriad.com/
Rosetta Genomics, Ltd. is a leading molecular diagnostics company advancing microRNA-based diagnostics discovered and developed through its proprietary microRNAs and platform technologies. Backed by a strong IP portfolio, Rosetta Genomics’ scientists have developed proprietary platform technologies for the identification, extraction, quantification, and analysis of microRNAs from a wide range of sample types. These technologies enable the identification and advancement of multiple diagnostic projects addressing critical unmet needs in cancer, cardiovascular diseases and other indications. The Company’s four commercial oncology tests have been launched in multiple countries worldwide via partners, and by a Company-led effort in the U.S. The Company is now working to develop additional tests in the cancer realm and in other fields.
Founded in 2000, Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta Genomics' testing services are commercially available through its Philadelphia-based CAP accredited, CLIA certified lab. Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award. For more information, visit http://rosettagenomics.com/
LunchTime Series Teleconference held on January 29, 2014: The first topic was "Abraxane in Metastatic Pancreatic Cancer with Gemcitabine"presented by: Robert Rodgers, PharmaD, Celgene Corporation. The second topic was "Billing and Coding Changes for 2014"presented by: Bobbi Buell, Principal, OnPoint Oncology, LLC. In case you missed the presentation, you can listen to the recording by dialing 1-888-203-1112 and enter the pass code 102472195#. This recording will be available for the next 30 days.
To view the handouts for the presentation, please email Danielle Overman at firstname.lastname@example.org
Mobile Health Library is a powerful and versatile platform that provides access to patient education materials, interactive videos, sample requests, and much more, all in 1 convenient, easy to use place. Novartis Oncology is committed to delivering innovative tools, such as Mobile Health Library to support the oncology community in its effort to advance the care of patients. When using a desktop:
Write in the search field “Novartis Oncology”
Once on the site, click accept terms
Then you will be at the Novartis HCP (Healthcare Provider) Resource Center
PANO – (Patient Assistance Now Oncology) reimbursement support services link www.oncologyaccessnow.com Hotline number: 800-282-7630.